FXYD5 (Dysadherin) may mediate metastatic progression through regulation of the β-Na+-K+-ATPase subunit in the 4T1 mouse breast cancer model

Irina Lubarski-Gotliv, Kuntal Dey, Yuri Kuznetsov, Vecheslav Kalchenco, Carol Asher, Haim Garty

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

FXYD5 is a Na+-K+-ATPase regulator, expressed in a variety of normal epithelia. In parallel, it has been found to be associated with several types of cancer and effect lethal outcome by promoting metastasis. However, the molecular mechanism underlying FXYD5 mediated invasion has not yet been identified. In this study, using in vivo 4T1 murine breast cancer model, we found that FXYD5-specific shRNA significantly inhibited lung cancer metastasis, without having a substantial effect on primary tumor growth. Our study reveals that FXYD5 participates in multiple stages of metastatic development and exhibits more than one mode of E-cadherin regulation. We provide the first evidence that FXYD5-related morphological changes are mediated through its interaction with Na+-K+-ATPase. Experiments in cultured 4T1 cells have indicated that FXYD5 expression may downregulate the β1 isoform of the pump. This behavior could have implications on both transcellular interactions and intracellular events. Further studies suggest that differential localization of the adaptor protein Annexin A2 in FXYD5-expressing cells may correlate with matrix metalloproteinase 9 secretion and adhesion changes in 4T1 wild-type cells.

Original languageEnglish
Pages (from-to)C108-C117
JournalAmerican Journal of Physiology - Cell Physiology
Volume313
Issue number1
DOIs
StatePublished - 7 Jul 2017
Externally publishedYes

Keywords

  • 4T1
  • Breast cancer
  • FXYD5 dysadherin
  • Metastasis
  • Na-K-ATPase

Fingerprint

Dive into the research topics of 'FXYD5 (Dysadherin) may mediate metastatic progression through regulation of the β-Na+-K+-ATPase subunit in the 4T1 mouse breast cancer model'. Together they form a unique fingerprint.

Cite this